Molecular modeling of AChE has been instrumental in designing new drugs for the treatment of Alzheimer’s disease, a condition characterized by a decrease in brain acetylcholine levels [28]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.